Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib

BMJ Case Reports

Volumn , Issue , 2012, Pages

  Khan, Afaq Ahmad ^a   Siraj, Fouzia ^a   Bhargava, Manorama ^a   Aggarwal, Shyam ^a  

^a SIR GANGA RAM HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD20 ANTIGEN; CREATININE; DEXAMETHASONE; GLOBULIN; M PROTEIN; THALIDOMIDE;

ADULT; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; BLOOD CELL COUNT; CASE REPORT; CYTOLOGY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOTHYROIDISM; KIDNEY FAILURE; LEUKOCYTOCLASTIC VASCULITIS; LYMPH NODE BIOPSY; LYMPH NODE HYPERPLASIA; LYMPHADENITIS; LYMPHOCYTIC INFILTRATION; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; MYELOMA; PALLOR; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; WEAKNESS; WEIGHT REDUCTION;

EID: 84872730128     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2012-007646     Document Type: Article

References (12)

1. Gaba AR, Stein RS, Sweet DL, et al. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978;69:86-90. (Pubitemid 8269654)
2. Izutsu K, Usuki K, Inoue K, et al. Polyclonal plasmacytosis in peripheral blood and leukocytoclastic vasculitis in Castleman's disease. Rinsho Ketsueki 1998;39:210-15.
3. Wolf M, Van Offel JF, Van de Velde A, et al. Multicentric plasma cell variant Castleman's disease presenting with cutaneous vasculitis and pulmonary parenchymal involvement in a patient with ankylosing spondylitis: case report and review of the literature. Acta Clin Belg 2011;66:305-10.
4. Jongsma TE, Verburg RJ, Geelhoed-Duijvestijn PH. Castleman's disease: a rare lymphoproliferative disorder. Eur J Intern Med 2007;18:87-9. (Pubitemid 46330783)
5. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74:1360-7. (Pubitemid 19227448)
6. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman's disease. Blood 2005;106:2627-32. (Pubitemid 41510733)
7. Lee FC, Merchant SH. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am J Hematol 2003;73:48-53. (Pubitemid 36504579)
8. Ide M, Kawachi Y, Izumi Y, et al. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur J Haematol 2006;76:119-23.
9. Richardson PG, Barlogie B, Berenson J, et al. A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17. (Pubitemid 36741588)
10. Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005;23:630-9. (Pubitemid 46224241)
11. Yuan ZG, Dun XY, Li YH, et al. Treatment of multicentric Castleman's disease accompanying multiple myeloma with bortezomib: a case report. J Hematol Oncol 2009;2:19.
12. Sobas MA, Alonso VN, Diaz AJ, et al. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant). Ann Hematol 2010;89:217-19.